Real-time Estimate
Tradegate
07:50:15 2024-04-25 am EDT
5-day change
1st Jan Change
85.98
EUR
+8.01%
+7.68%
+42.11%
Sales 2024 *
822M
882M
Sales 2025 *
900M
966M
Capitalization
4.12B
4.42B
Net income 2024 *
167M
179M
Net income 2025 *
207M
222M
EV / Sales 2024 *
4.97
x
Net cash position
2024
*
39.02M
41.86M
Net cash position
2025
*
169M
181M
EV / Sales 2025 *
4.39
x P/E ratio 2024 *
24.8
x
P/E ratio 2025 *
20.3
x
Employees
1,925
Yield 2024 *
1.37%
Yield 2025 *
1.63%
Free-Float
35.68%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment
Apr. 02
MT
Rovi, Partners to Form Entity for Advanced Therapies R&D
Mar. 12
MT
Rovi explores sale of unit that makes drugs for third parties
Mar. 07
RE
Rovi Responds to Press Speculation Regarding Contract Development Business Deal
Mar. 07
MT
Transcript : Laboratorios Farmaceuticos Rovi, S.A., 2023 Earnings Call, Feb 27, 2024
Feb. 27
The Ibex-35 opts for caution as corporate results continue to trickle in.
Feb. 27
RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 25
CI
US FDA finds control lapses at Moderna manufacturing plant
Dec. 15
RE
Italy, Spain stocks hit peaks after over 20% rally in 2023
Nov. 30
RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023
Nov. 08
CI
Transcript : Laboratorios Farmaceuticos Rovi, S.A., H1 2023 Earnings Call, Jul 26, 2023
23-07-26
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023
23-07-26
CI
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.
23-07-26
CI
Global markets live: Macy's, Salesforce, Dollar General, Nordstrom, Exxon...
23-06-01
Rovi denies being investigated for alleged public subsidies
23-06-01
RE
More news
7 maravillas frente a 7 magníficos, pólvora y Gatekeepers
Apr. 03
Le bric-à-brac de Zonebourse : 7 Merveilles vs 7 Magnifiques, poudre à canon et Gatekeepers
Apr. 03
Bolsa de Madrid: Después de Semana Santa, algo va mal
Apr. 03
AVIS D'ANALYSTES DU JOUR : Veolia, Soitec, Rheinmetall, Air France, Infineon, Interparfums, Voltalia...
Apr. 03
EN DIRECTO DESDE LOS MERCADOS: Iberdrola, CaixaBank, Stellantis, Airbus, Banco Santander, Tubacex, PostNL, United Airlines...
Mar. 25
More news 1 day +7.10%
1 week +7.11%
Current month +5.19%
1 month +5.85%
3 months +33.70%
6 months +72.62%
Current year +41.36%
More quotes
Managers
Title Age Since
Chief Executive Officer
-
93-12-31
Director of Finance/CFO
-
99-12-31
Chief Tech/Sci/R&D Officer
-
-
Members of the board
Title Age Since
Director/Board Member
-
94-12-31
Director of Finance/CFO
-
99-12-31
Chief Executive Officer
-
93-12-31
More insiders
Date
Price
Change
Volume
24-04-25
85.55
+7.47%
105 145
24-04-24
79.6
-1.06%
113,717
24-04-23
80.45
+1.26%
36,685
24-04-22
79.45
+0.06%
37,668
24-04-19
79.4
-0.06%
59,981
Delayed Quote
BME, April 25, 2024 at 05:50 am EDT
More quotes
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows:
- pharmaceutical products manufactured under contract (49%);
- prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.;
- diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals.
Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%).
Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
More about the company
Last Close Price
79.6
EUR
Average target price
79.18
EUR
Spread / Average Target
-0.53%
Consensus
1st Jan change
Capi.
+41.36% 4.41B +25.61% 660B +23.21% 562B -5.24% 358B +16.49% 322B +8.28% 297B +12.74% 219B -9.69% 196B +6.66% 199B -8.75% 149B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1